Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05426681 · ClinicalTrials.gov registry record · Phase 1

Spinal Cord Injury Neuroprotection With Glyburide

A Phase 1 study of Acute Spinal Cord Injury, sponsored by Francis Farhadi.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT05426681 is a Phase 1 study of Acute Spinal Cord Injury that is actively recruiting participants, run by Francis Farhadi. The registered enrollment target is 12 participants, below the 40-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05426681, a Phase 1 study of Acute Spinal Cord Injury, is actively recruiting participants, sponsored by Francis Farhadi.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.

Conditions Studied

Interventions

  • DRUG GlyBURIDE Oral Tablet

Study Locations (1)

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-07-07
Est. Completion 2028-05
Phase Phase 1

Sponsor

Francis Farhadi

8 total trials

What the Registry Record Tells You About NCT05426681

The ClinicalTrials.gov registry entry for NCT05426681 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 40-participant average among 8 other Acute Spinal Cord Injury trials with a reported enrollment target (70% lower). The listed sponsor is Francis Farhadi, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which GlyBURIDE Oral Tablet is the first listed.

NCT05426681 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT05426681 about?

NCT05426681 is a clinical study titled "Spinal Cord Injury Neuroprotection With Glyburide". To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.

What is the current status of trial NCT05426681?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-07-07. Estimated completion is 2028-05.

What conditions does trial NCT05426681 study?

This clinical trial studies the following conditions: Acute Spinal Cord Injury.

What interventions are being tested in trial NCT05426681?

The interventions under investigation include: GlyBURIDE Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT05426681?

This trial is sponsored by Francis Farhadi, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05426681 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.